Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

6 Major Investment Themes Shaping 2026

View original at finance.yahoo.com
6 Major Investment Themes Shaping 2026 The bull market remains intact, and the opportunity set heading into 2026 is plentiful. 2025 delivered another year of strong equity performance, with the S&P 500 up roughly 16% and the Nasdaq 100 gaining nearly 21% as of this writing…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There are few signs of an imminent economic slowdown

    80% confidence
  • Solar is the fastest growing and most scalable source of new energy at a time when electricity demand is soaring

    80% confidence
  • Traditional 60/40 stock-bond portfolio no longer reflects today's market realities, suggesting 60/20/20 approach with gold replacing half bond allocation

    80% confidence
  • The bull market remains intact, and the opportunity set heading into 2026 is plentiful

    80% confidence
  • Lithium-ion battery pack costs declined 20% over past year, reaching record low of $108 per kilowatt-hour

    80% confidence
  • Solar is now among cheapest sources of new power generation across much of United States

    80% confidence
  • Earnings for rest of S&P 500 projected to grow 10.8% in 2026, up from 8.3% in 2025, 4.4% in 2024, and -4.8% in 2023

    80% confidence
  • Bitcoin has never had two consecutive years of annual losses

    80% confidence
  • The AI infrastructure cycle is far from complete and current phase resembles late-1990s infrastructure buildout

    80% confidence
  • Gold has risen nearly 70% this year and more than doubled S&P 500's return over past three years

    80% confidence
  • Gold is now the anti-fragile asset to own, rather than Treasuries. High-quality equities and gold are the best hedges

    80% confidence
  • Total AI-related capital expenditures approach $1 trillion

    80% confidence
  • Big Tech companies continue to combine strong revenue growth, rising profitability, and elevated yet defensible valuations

    80% confidence
  • US LNG export capacity set to expand meaningfully

    80% confidence
  • Global AI-related capex is projected to exceed $500 billion

    80% confidence
  • Photovoltaic module costs have fallen by roughly 90% over past decade

    80% confidence
  • Estimated 2025 earnings growth of 21.7% on 11.9% higher revenues for Magnificent Seven

    80% confidence
  • Artificial intelligence was a key driver of returns, cementing itself as the most important business and technological shift since the internet

    80% confidence
  • Battery costs down nearly 90% over past decade

    80% confidence
  • Total 2026 earnings for Magnificent Seven expected to rise 16.5% on 15% revenue growth

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
6 Major Investment Themes Shaping 2026 — Source | Via News | ViaNews EU